Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasm, Residual 1Medulloblastoma 1Leukemia, Hairy Cell 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 4Cyclophosphamide 4blinatumomab 3Rituximab 3Lenalidomide 2Immunotherapy, Adoptive 2venetoclax 1trastuzumab deruxtecan 1tisagenlecleucel 1pembrolizumab 1obinutuzumab 1niraparib 1nilotinib 1isatuximab 1acalabrutinib 1Zymosan 1Whole-Body Irradiation 1Trastuzumab 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Pentostatin 1NKTR-255 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Immunotherapy 1Imatinib Mesylate 1Histamine Antagonists 1Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm, Residual × Histamine Antagonists × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡